VC Cell Therapy

What VC Cell Therapy does

VC Cell Therapy Inc. (VCCT) is a Japanese biotechnology company, founded March 8, 2021 as a wholly-owned subsidiary of Vision Care Inc., developing iPS cell-derived regenerative cell therapies for retinal degenerative diseases. The company operates from the Kobe Eye Center in Kobe, Japan, and via a US subsidiary (VCCT USA inc., Escondido, California, established June 2024) for North American market entry.

VCCT's product portfolio comprises five pipeline candidates built on a single iPS cell technology platform: MastCT-01 (allogeneic iPSC-derived RPE), MastCT-02 (autologous iPSC-derived RPE), MastCT-03 (HLA gene-edited iPSC-derived RPE, partnered with J-TEC), MastCT-PR (allogeneic iPSC-derived retinal organoids), and MastCT-CP (combined RPE + organoid). The proprietary technology stack includes the RPE Strip (RPE凝集紐) formulation enabling minimally invasive subretinal transplantation, retinal organoid generation via the SFEBq/BMP4 method, HLA gene editing for immune evasion in allogeneic products, and automated clinical-grade cell manufacturing using the Maholo LabDroid humanoid robot integrated with AI (validated by an 88% iPSC-RPE production efficiency gain). R&D operates from the MHLW-licensed FiRst cell processing facility (~357 m²) under Japan's Regenerative Medicine Safety Law.

The commercial model is currently pre-revenue on the cell therapy side, with products supplied only through clinical research at Kobe City Eye Hospital; revenue mechanics remain undisclosed and pricing for regenerative medicine products is not publicly available. A complementary revenue stream is emerging through collaborative research services — notably the May 2025 Eisai agreement to develop a retinal organoid-based drug toxicity testing platform — leveraging the SFEBq organoid technology as a pharma services offering. The company has raised approximately 1.7 billion yen (~USD 11.3M) cumulatively via a 2021 convertible note, 2023 capital loans from Japanese institutional lenders, and a 2023 equity round from strategic investors Sysmex, DAI-DAN, and YASKAWA Electric. Future commercialization will rely on capital alliances with J-TEC (Japan product launch), Kuraray (cell culture materials supply), and an international therapy chain model targeting Asia-Pacific hospital partners.

Name

VC Cell Therapy

Legal name

株式会社 VC Cell Therapy

Website

https://vcct.jp

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

VC Cell Therapy is a Japanese biotech subsidiary of Vision Care Inc. developing iPS cell-derived retinal cell therapies (MastCT-01/02/03/PR/CP) for retinitis pigmentosa, AMD, and other retinal degenerative diseases, served through clinical research at Kobe City Eye Hospital and an emerging pharma services stream via Eisai.

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Cell Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• IPS cell therapy
• Retinal cell therapy
• Regenerative medicine products
• Retinal pigment epithelium transplantation
• Cell therapy manufacturing

Headquarters

HQ city

Kobe

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure

Revenue model

1. Regenerative Medicine Cell Products: VC Cell Therapy develops and commercializes iPS cell-derived retinal cell therapy products (RPE cells, retinal organoids) for the treatment of retinal degenerative diseases. Revenue is generated through the sale of cell therapy products for clinical use, with multiple pipeline products (MastCT-01, MastCT-02, MastCT-03, MastCT-PR, MastCT-CP) at various clinical stages. The company is working toward full-scale commercialization in Japan and global expansion.
2. Collaborative Research Services: The company conducts collaborative research with pharmaceutical companies (e.g., Eisai) using its retinal organoid technology platform for drug toxicity testing, generating research service revenue.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

VC Cell Therapy (VCCT) develops and manufactures iPS cell-derived retinal cell therapy products — including RPE cells and retinal organoids — for the treatment of retinal degenerative diseases such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP). The company supplies these products to clinical research institutions (notably Kobe City Eye Hospital) and engages in collaborative research with pharmaceutical companies (e.g., Eisai) for retinal organoid-based drug toxicity testing. Manufacturing is conducted at the company's licensed cell processing facility FiRst.

Product overview

VCCT Inc. is a seed/growth-stage biotechnology company developing a portfolio of ex vivo cell therapy products for ocular diseases, founded in 2021 as a subsidiary of Vision Care Inc. and a member of the Kobe Eye Center initiative. The company's product portfolio comprises five pipeline products (MastCT-01 through MastCT-CP), all built on iPS cell technology: MastCT-01 (allogeneic iPSC-derived RPE strip) and MastCT-02 (autologous iPSC-derived RPE) address retinal degeneration via RPE cell transplantation; MastCT-03 (genome-edited HLA-deficient iPSC-derived RPE) improves safety for allogeneic use; MastCT-PR (allogeneic retinal organoid-derived retinal sheet) targets photoreceptor cell regeneration; and MastCT-CP (combined RPE plus retinal organoid) treats patients who have lost both RPE and photoreceptors. Supporting these products are three core technology platforms: the RPE Strip formulation (a 200μm × 2cm aggregated cell strip for minimally invasive transplantation), Retinal Organoid Technology (3D retinal tissue via SFEBq/BMP4 differentiation), and Robotic Cell Manufacturing using humanoid robot Maholo and AI for automated, reproducible clinical-grade cell production at the FiRst facility.

Differentiator

Problem solved

Functional benefit

Products and services

• MastCT-01 Allogeneic iPSC-derived retinal pigment epithelium (RPE) cells formulated as a strip-like transplant for treating retinal degenerative diseases associated with RPE degeneration. Applied in ongoing clinical research at Kobe City Eye Hospital.
• MastCT-02 Autologous iPSC-derived RPE cells for age-related macular degeneration (AMD), using the patient's own iPS cells matched to the genetic background to avoid immune rejection after transplantation.
• MastCT-03 Genome-edited iPSC-derived RPE cells engineered to lack HLA molecules, designed as an allogeneic cell product with reduced immune rejection risk for treating various retinal degenerative diseases associated with RPE degeneration. Under capital/business alliance with Japan Tissue Engineering (J-TEC) for accelerated commercialization.
• MastCT-PR Allogeneic iPS cell-derived retinal organoids differentiated from donor iPS cells; rectangular-shaped retinal tissue excised from organoids is transplanted under the patient's retina for treatment of retinitis pigmentosa, AMD, and other retinal degeneration diseases. Used in clinical research at Kobe City Eye Hospital.
• MastCT-CP Combination product pairing allogeneic human iPS cell-derived RPE cells and retinal cell organoids, designed to treat patients with progressive retinal degeneration who have lost both RPE and photoreceptor cells.
• RPE Strip (RPE凝集紐) Strip-like formulation of iPS-derived RPE cells approximately 200μm in diameter and 2cm in length, developed to overcome limitations of both RPE cell sheets and cell suspension methods. Enables minimally invasive targeted transplantation with cells expanding into a monolayer sheet post-transplant. Used clinically since November 2022.
• Retinal Organoid-Based Drug Toxicity Testing Platform Drug toxicity testing service for pharmaceutical partners using iPSC-derived retinal organoids under collaborative research agreements. VCCT contributes retinal organoid generation and analysis technologies; combines with partner expertise in drug discovery and toxicity assessment.

Quantifiable outcome

• 7+ years of stable graft maintenance without tumorigenesis or abnormal cell proliferation post-transplantation
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Kuraray Co., Ltd. (株式会社クラレ)coreStrategic or Co-development Partner · 26 December 2025Capital and business alliance combining Kuraray's cell culture material development capabilities (including Scopova) with VCCT's cell manufacturing and cell therapy end-to-end expertise. The goal is to develop innovative cell culture materials and deliver high-quality cell pharmaceutical products stably to a larger number of patients, contributing to the advancement of regenerative medicine.
• Eisai Co., Ltd.coreStrategic or Co-development Partner · 12 May 2025VCCT entered a collaborative research agreement with Eisai to develop a drug toxicity testing platform utilizing iPSC-derived retinal organoids. Eisai brings internationally recognized expertise in toxicity assessment using pluripotent stem cell-derived cardiomyocytes. VCCT contributes its retinal organoid generation and analysis technologies. The collaboration aims to create a novel toxicity testing platform for safer and more effective pharmaceutical development.
• Japan Tissue Engineering Co., Ltd. (J-TEC)coreStrategic or Co-development Partner · 27 December 2024Capital and business alliance to accelerate practical application of iPS cell-based regenerative medical product (development name: MastCT-03) for retinal degenerative diseases. J-TEC has successfully commercialized the highest number of regenerative medical products among Japanese manufacturers, totaling five. The alliance aims to leverage J-TEC's commercialization expertise and regulatory experience to achieve faster market entry for VCCT's genome-edited iPSC-derived RPE product.
• Ritsumeikan University Faculty of Pharmaceutical SciencesminorStrategic or Co-development Partner · 22 May 2024Educational and research cooperation agreement for talent exchange and collaborative research in regenerative and gene therapy. The partnership aims to develop human resources capable of handling cell and gene therapy development and formulation.
• Kobe City Eye Hospital (神戸市立神戸アイセンター病院)coreStrategic or Co-development PartnerPrimary clinical research collaborator conducting multiple clinical studies of iPS cell-derived retinal cell therapies. The hospital is part of the Kobe Eye Center initiative that unifies research, clinical practice, and patient care for the benefit of ocular disease patients.
• Robotic Biology Institute Inc. (ロボティック・バイオロジー・インスティテュート株式会社)coreTechnology or IntegrationPartnership for development and deployment of humanoid robot Maholo LabDroid for automated iPS cell cultivation and differentiation. RBI developed the robot system capable of performing cell culture procedures with human-equivalent dexterity. VCCT uses Maholo for clinical cell manufacturing at its FiRst facility, achieving stable and reproducible production of iPS-RPE cells.
• RIKEN (理化学研究所)coreStrategic or Co-development PartnerOrigin of VCCT's technology; VCCT evolved from the RIKEN Laboratory for Retinal Regeneration led by Masayo Takahashi. Ongoing collaborative research on robotic cell manufacturing, retinal organoid development, and iPS cell differentiation protocols. Co-authors on multiple scientific publications.
• Ministry of Economy, Trade and Industry (METI) - Government ProgramscoreOthersMultiple METI programs supporting VCCT: (1) Go-Tech 2025 R&D program for cartridge development for iPS cell product injection/surgery; (2) 2022 supplementary budget for regenerative/cell/gene therapy social implementation infrastructure; (3) 2024 healthcare industry international expansion program for building cross-border retinal regenerative medicine platform.
• Ministry of Health, Labour and Welfare (MHLW)coreOthersGranted Special Cell Processing Product Manufacturing License (Facility No. FA5220002) to VCCT's FiRst facility on October 20, 2022, under Japan's Regenerative Medicine Safety Law, enabling clinical and commercial cell product manufacturing.

Scale indicators4 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Lineage Cell Therapeutics: U.S. clinical-stage biotech developing OpRegen, an allogeneic RPE cell therapy for dry AMD with geographic atrophy. Most directly comparable to VCCT's MastCT-01/02/03 programs as a competing retinal cell therapy for AMD with similar mechanism and target indication.
• jCyte: Clinical-stage company developing jCell, a retinal progenitor cell therapy for retinitis pigmentosa. Directly comparable to VCCT's MastCT-PR retinal organoid program in indication, route of administration, and patient population.
• Healios K.K. Japanese regenerative medicine company developing stem cell therapies (e.g., HLCM051 for stroke, stem cell-derived products) and partnered with major Japanese pharma. Comparable as a Japanese peer in iPSC/stem cell-derived regenerative medicine with overlapping manufacturing and regulatory pathway.
• Japan Tissue Engineering Co., Ltd. (J-TEC): Japan's leading commercial regenerative medicine company (a subsidiary of FUJIFILM), with five approved regenerative products including autologous cartilage and corneal epithelial sheets. Direct competitor and now capital/business alliance partner of VCCT for MastCT-03 commercialization.
• BlueRock Therapeutics: Bayer-owned clinical-stage cell therapy company developing iPSC-derived dopaminergic neurons and other engineered cell therapies. Comparable as an iPSC-derived cell therapy developer using similar pluripotent stem cell differentiation and GMP manufacturing approaches, with deeper capital base.

Emerging players

• Century Therapeutics: U.S. clinical-stage biotech developing iPSC-derived allogeneic NK and T cell therapies (with gene editing for immune evasion). Comparable technology platform to VCCT's HLA-edited iPSC-RPE in using iPSC + gene editing to enable off-the-shelf allogeneic cell products.
• Fate Therapeutics: U.S. clinical-stage biotech with a broad iPSC-derived NK and T cell therapy pipeline using similar induced pluripotent stem cell and gene editing approaches. Comparable as an iPSC-platform cell therapy competitor, though focused on oncology indications rather than ophthalmology.

Broad incumbents

• Sumitomo Pharma Co., Ltd. Major Japanese pharmaceutical company and patent licensor (through Helios/Sumitomo) for the iPSC-to-RPE differentiation patent underlying VCCT's MastCT-02 program. A broad incumbent with regenerative medicine and ophthalmology interests that overlap with VCCT's commercial space.
• Regeneron Pharmaceuticals: Large biopharmaceutical company with leading ophthalmology franchise (Eylea, aflibercept) used in AMD treatment that VCCT's MastCT products would compete against in clinical practice. Comparable as the dominant standard-of-care incumbent in the wet AMD market VCCT targets.

Others

• RIKEN (Center for Biosystems Dynamics Research): Japanese national research institute where VCCT's core iPSC-RPE and retinal organoid technology originated under Masayo Takahashi. Functions as a research partner and patent licensor rather than direct competitor, but its ongoing retinal regeneration program shapes VCCT's scientific landscape.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VC Cell Therapy